Despite the benefits of endocrine agents for many patients, a large proportion of patients with ERα-positive breast cancer progress on anti-estrogen or aromatase inhibitor therapies, or relapse following initial response [3, 4]. Here, CYP19A1 is linked to breast carcinoma.